Trial Profile
A Phase I, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose and Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Peripheral ischaemia; Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 06 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 06 Jun 2014 New trial record